Clinical Health Updates

Methylprednisolone improves outcomes in ARDS

Clinical Question:
Does prolonged methylprednisolone administered to patients with ARDS reduce lung injury and improve patient outcomes?

Bottom Line:
Methylprednisolone initiated early in the course of acute respiratory distress syndrome (ARDS) reduces the duration of mechanical ventilation and mortality in the intensive care unit (ICU).

Reference:
Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized trial. Chest 2007;131:954-963.

Study Design:
Randomized controlled trial (double-blinded)

Synopsis:
The authors determined the effects of low-dose prolonged methylprednisolone infusion on lung function in patients with early severe Acute Respiratory Distress Syndrome (ARDS). Randomized, double-blind, placebo-controlled trial was done. They did at ICUs of five hospitals in Memphis. Ninety-one patients with severe early ARDS (